Literature DB >> 21570905

The clinical and electrodiagnostic characteristics of Pompe disease with post-enzyme replacement therapy findings.

Lisa D Hobson-Webb1, Stephanie Dearmey, Priya S Kishnani.   

Abstract

OBJECTIVE: Pompe disease is a neuromuscular disorder that was progressive and fatal prior to enzyme replacement therapy (ERT). The advent of treatment has made early recognition imperative. Electrodiagnostic (EDx) studies represent a valuable diagnostic tool in Pompe disease, but there has been little contemporary data.
METHODS: The records of 29 patients with Pompe disease who had undergone EDx evaluation at Duke University Medical Center from 1999 to 2010 were reviewed.
RESULTS: Seventeen children and twelve adults comprised the group. The clinical characteristics of both groups did not differ from expected. Needle electromyography demonstrated spontaneous activity (SA) in 80% of children and 83% of adults. Myotonic discharges were found in 53% of children and 72% of adults, often isolated to the paraspinal muscles in adults. Eight patients had EDx studies performed after ERT with 3 showing improvement after therapy, despite clinical improvement in 6 of 8.
CONCLUSIONS: EDx studies remain a helpful tool in diagnosing Pompe disease, but do not appear to be sensitive for monitoring response to ERT based upon this limited sample. SIGNIFICANCE: Paraspinal examination is necessary in adults with symptoms suggestive of Pompe disease, as abnormalities may be isolated to this region. Standard EDx studies are not sufficient to monitor early response to ERT and further research on potential biomarkers is needed.
Copyright © 2011 International Federation of Clinical Neurophysiology. Published by Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21570905     DOI: 10.1016/j.clinph.2011.04.016

Source DB:  PubMed          Journal:  Clin Neurophysiol        ISSN: 1388-2457            Impact factor:   3.708


  14 in total

Review 1.  Positive muscle phenomena--diagnosis, pathogenesis and associated disorders.

Authors:  Hans G Kortman; Jan H Veldink; Gea Drost
Journal:  Nat Rev Neurol       Date:  2012-01-24       Impact factor: 42.937

2.  Pearls & Oy-sters: clues to the diagnosis of adult-onset acid maltase deficiency.

Authors:  Tania B Beltran Papsdorf; James F Howard; Nizar Chahin
Journal:  Neurology       Date:  2014-03-04       Impact factor: 9.910

Review 3.  Guidelines on clinical presentation and management of nondystrophic myotonias.

Authors:  Bas C Stunnenberg; Samantha LoRusso; W David Arnold; Richard J Barohn; Stephen C Cannon; Bertrand Fontaine; Robert C Griggs; Michael G Hanna; Emma Matthews; Giovanni Meola; Valeria A Sansone; Jaya R Trivedi; Baziel G M van Engelen; Savine Vicart; Jeffrey M Statland
Journal:  Muscle Nerve       Date:  2020-05-27       Impact factor: 3.217

4.  Effect of enzyme replacement therapy in late onset Pompe disease: open pilot study of 48 weeks follow-up.

Authors:  Jin-Sung Park; Hye-Gyung Kim; Jin-Hong Shin; Young-Chul Choi; Dae-Seong Kim
Journal:  Neurol Sci       Date:  2014-11-12       Impact factor: 3.307

Review 5.  Enzyme replacement therapy in late-onset Pompe disease: a systematic literature review.

Authors:  Antonio Toscano; Benedikt Schoser
Journal:  J Neurol       Date:  2012-08-28       Impact factor: 4.849

Review 6.  Electrodiagnostic evaluation of myopathies.

Authors:  Sabrina Paganoni; Anthony Amato
Journal:  Phys Med Rehabil Clin N Am       Date:  2012-10-16       Impact factor: 1.784

7.  Altered activation of the tibialis anterior in individuals with Pompe disease: Implications for motor unit dysfunction.

Authors:  Manuela Corti; Barbara K Smith; Darin J Falk; Lee Ann Lawson; David D Fuller; S H Subramony; Barry J Byrne; Evangelos A Christou
Journal:  Muscle Nerve       Date:  2015-04-24       Impact factor: 3.217

8.  Clinical features and predictors for disease natural progression in adults with Pompe disease: a nationwide prospective observational study.

Authors:  Nadine A M E van der Beek; Juna M de Vries; Marloes L C Hagemans; Wim C J Hop; Marian A Kroos; John H J Wokke; Marianne de Visser; Baziel G M van Engelen; Jan B M Kuks; Anneke J van der Kooi; Nicolette C Notermans; Karin G Faber; Jan J G M Verschuuren; Arnold J J Reuser; Ans T van der Ploeg; Pieter A van Doorn
Journal:  Orphanet J Rare Dis       Date:  2012-11-12       Impact factor: 4.123

9.  Clinical features of Pompe disease.

Authors:  Fiore Manganelli; Lucia Ruggiero
Journal:  Acta Myol       Date:  2013-10

10.  Early is better? A new algorithm for early diagnosis in late onset Pompe disease (LOPD).

Authors:  Antonio Toscano; Federica Montagnese; Olimpia Musumeci
Journal:  Acta Myol       Date:  2013-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.